ND SB2156

Amends the drug use review board to consist of 17 members including physicians, pharmacists, a consumer representative, and pharmaceutical industry representatives, with the pharmacy administrator and medical consultant serving as ex officio nonvoting members.

Allows board members appointed as physicians or pharmacists to serve without meeting the state residency requirement if providing services through telemedicine or telepharmacy, and allows pharmaceutical industry representatives to serve without state residency requirements.

Changes the prior authorization program to prohibit substantially all drugs in antipsychotics, antidepressants, anticonvulsants, antiretrovirals, and antineoplastic agents for individuals 18 years and older, replacing stimulant medication restrictions with immunosuppressants for organ transplant rejection.

For individuals under 18 years old, replaces prior authorization restrictions on stimulant medications with immunosuppressants, while maintaining restrictions on other psychotropic medication classes with an exception when a patient has five or more concurrent psychotropic prescriptions.

Authorizes the department to negotiate additional drug rebates from manufacturers and join multistate supplemental drug rebate pools, requiring other manufacturers to be allowed to match any rebates negotiated outside the pool.